AUROPHARMA · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 41/100 — Quality 60 · Valuation 13 · Growth 21 · Momentum 74
| Share price | ₹1,559.60 |
| Market cap | ₹70,881 Cr |
| P/E ratio | 20.3 |
| P/B ratio | 2.0 |
| ROE | 11.5% |
| ROCE | 15.7% |
| Dividend yield | 0.33% |
| Book value | ₹603.39 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹33,653 Cr | ₹3,503 Cr | 20.0% |
| 2025 | ₹31,724 Cr | ₹3,484 Cr | 21.0% |
| 2024 | ₹29,002 Cr | ₹3,169 Cr | 20.0% |
| 2023 | ₹24,855 Cr | ₹1,928 Cr | 15.0% |
| 2022 | ₹23,455 Cr | ₹2,647 Cr | 19.0% |
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HI